Latest Research

Researchers have developed NbHB1, a camelid-derived nanobody, to purify recombinant Hepatitis B surface antigen virus-like particles (rHBsAg-VLPs) with large scale performance. This approach combines high specificity, excellent reusability, and scalability — all essential for modern vaccine production.

Adeno‑associated virus serotype 8 (AAV8) is a gold standard viral vector in gene therapy. However, conventional antibody-based affinity columns suffer from low ligand density, poor stability, and high cost, which limit throughput and product quality. A new study presents a custom nanobody (Nb9) affinity resin that exhibits 9.12 mg ligand/mL, enables clean one-step AAV8 purification, and maintains over 70% binding capacity after 20 purification cycles, challenging the limitations of traditional resins. 

Are engineered extracellular vesicles (EVs)  the new frontier for delivering genome editors and therapeutic payloads? In a landmark 2025 Nature Communications study led by Samir EL Andaloussi et al., researchers engineered EVs to deliver multimodal cargo—including CRISPR/Cas9 RNPs and Cre recombinase—with remarkable in vitro and in vivo efficiency.